MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Asthmatx, Inc. today announced it has decided not to proceed with its initial public offering as the Company has decided to pursue an alternative strategic option. No shares of common stock have been sold pursuant to the Registration Statement.
Piper Jaffray & Co. and Bear, Stearns & Co. Inc. were slated to serve as joint book-running managers for the offering, with First Albany Capital Inc. and Jefferies & Company, Inc. serving as co-managers.
About Asthmatx Inc.
Asthmatx Inc. is a medical device company focused on developing and commercializing a novel therapeutic treatment for asthma. Asthmatx has developed the Alair System®, which consists of a single-use device and a controller that delivers controlled thermal energy to the airways of adult patients to reduce the mass of airway smooth muscle in an investigative outpatient bronchoscopic procedure known as Bronchial Thermoplasty.
For further information, contact investor relations at 650-810-1106.
Contact: Asthmatx Inc. Chris Lowe, 650-810-1106
Source: Asthmatx Inc.
